The goal of this project is to study the interaction of radiotherapy and molecularly targeted agents. This project focuses on expanding drugs that show synergy in vitro to the in vivo setting, with the goal of translation to the clinic. This is a translational project. We begin in the laboratory testing drugs in combination with radiotherapy in vitro. Once in vitro sensitivity is comfirmed then we do in vivo work with sc or ic animal models. If a drug is shown to sensitize tumor cells to radiation then we bring it to the clinic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIASC010373-13
Application #
8763710
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
2013
Total Cost
$1,037,360
Indirect Cost
Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Baschnagel, Andrew; Russo, Andrea; Burgan, William E et al. (2009) Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 8:1589-95
Tofilon, Philip J; Camphausen, Kevin (2009) Molecular targets for tumor radiosensitization. Chem Rev 109:2974-88
Camphausen, Kevin (2009) Seminars in Radiation Oncology. Introduction. Semin Radiat Oncol 19:141
Chakraborty, Mala; Gelbard, Alexander; Carrasquillo, Jorge A et al. (2008) Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer Immunol Immunother 57:1173-83
Kil, Whoon Jong; Cerna, David; Burgan, William E et al. (2008) In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 14:931-8
Kumaraswamy, Sandhya; Chinnaiyan, Prakash; Shankavaram, Uma T et al. (2008) Radiation-induced gene translation profiles reveal tumor type and cancer-specific components. Cancer Res 68:3819-26
Chinnaiyan, Prakash; Cerna, David; Burgan, William E et al. (2008) Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 14:5410-5
Citrin, Deborah; Camphausen, Kevin (2008) Advancement of antiangiogenic and vascular disrupting agents combined with radiation. Cancer Treat Res 139:153-71
Chakraborty, Mala; Wansley, Elizabeth K; Carrasquillo, Jorge A et al. (2008) The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res 14:4241-9